{"id":"https://openalex.org/G1745570270","display_name":"Alteraciones moleculares involucradas en los mecanismos de refractariedad y reca\u00edda de la Leucemia Mieloide Aguda: Implicaciones terap\u00e9uticas.","description":"La Leucemia Mieloide Aguda (LMA) es el tipo de leucemia aguda m\u00e1s frecuente en adultos; en Espa\u00f1a se diagnostican 3.000 casos al a\u00f1o, el 60% resultan mortales durante los 3 primeros a\u00f1os. En los \u00faltimos 20 a\u00f1os, a pesar de la estratificaci\u00f3n pron\u00f3stica citogen\u00e9tica y el empleo del trasplante alog\u00e9nico de m\u00e9dula \u00f3sea, no se ha conseguido mejorar la supervivencia de los pacientes. Por ello es crucial no solo conocer el perfil mutacional al diagn\u00f3stico (caracterizado en el proyecto coordinado concedido previamente, PI13/2387-PI13/1640) sino conocer los mecanismos de resistencia a f\u00e1rmacos asociados al perfil mutacional, causantes de la refractariedad y de las reca\u00eddas de la enfermedad.     Las objetivos del proyecto son: 1. Dise\u00f1o de un panel de secuenciaci\u00f3n masiva para detectar reordenamientos estructurales, e incorporaci\u00f3n en el panel actual que detecta mutaciones y variaci\u00f3n del n\u00famero de copias (CNV) en la LMA; se utilizar\u00e1n t\u00e9cnicas de captura ex\u00f3nica para poder incorporar el estudio de las translocaciones al panel validado en el proyecto anterior, y se validar\u00e1 en 200 pacientes con LMA al diagn\u00f3stico. 2. Validaci\u00f3n funcional de los genes/asociaci\u00f3n de genes identificados en los distintos grupos pron\u00f3stico; se emplear\u00e1n herramientas de edici\u00f3n g\u00e9nica y t\u00e9cnicas de fosfoprote\u00f3micas, transcript\u00f3micas y metabol\u00f3micas. 3. Estudio de la implicaci\u00f3n de dichas alteraciones en el establecimiento del clon fundamental en las reca\u00eddas mediante NGS; los clones resistentes se seleccionar\u00e1n tras el tratamiento ex vivo con los f\u00e1rmacos a estudio. 4. Validaci\u00f3n cl\u00ednica de la tecnolog\u00eda NGS desarrollada para estudiar enfermedad m\u00ednima residual (EMR)en el proyecto PI13/2387.","funder_award_id":"PI16/01530","funder":{"id":"https://openalex.org/F4320334923","display_name":"Instituto de Salud Carlos III","doi":"https://doi.org/10.13039/501100004587"},"funded_outputs":["https://openalex.org/W34070172","https://openalex.org/W2611418188","https://openalex.org/W2765615347","https://openalex.org/W2883674899","https://openalex.org/W2884808707","https://openalex.org/W2885961002","https://openalex.org/W2905078270","https://openalex.org/W2966120190","https://openalex.org/W2994038994","https://openalex.org/W3008578234","https://openalex.org/W3046640968","https://openalex.org/W3100553263","https://openalex.org/W3163534579","https://openalex.org/W3163823358","https://openalex.org/W4383645606"],"funded_outputs_count":15,"parent_awards":[],"sub_awards":[],"sub_awards_count":0,"amount":99220.0,"currency":"EUR","amount_usd":104587.8,"amount_usd_basis":"daily_rate","recipients":[],"recipient_countries":[],"recipient_regions":[],"research_scope":{"is_research":true,"basis":"funder_default","tier":1},"funding_type":"grant","funder_scheme":null,"start_date":"2017-01-01","end_date":"2019-12-31","start_year":2017,"end_year":2019,"landing_page_url":"https://portalfis.isciii.es/proyecto?idProyecto=PI16/01530","doi":null,"provenance":"portal_fis_isciii","lead_investigator":{"given_name":"Rosa Maria","family_name":"Ayala Diaz","orcid":null,"role_start":null,"affiliation":{"name":"FUNDACION INVESTIGACION BIOMEDICA HOSPITAL 12 DE OCTUBRE","country":"ES","ids":null},"author":{"id":"https://openalex.org/A5080601782","display_name":"Rosa Mar\u00eda Ayala","orcid":"https://orcid.org/0000-0002-2699-8353"},"institutions":[{"id":"https://openalex.org/I4210086614","display_name":"Research Institute Hospital 12 de Octubre","ror":"https://ror.org/002x1sg85","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210086614"]}]},"co_lead_investigator":null,"investigators":null,"works_api_url":"https://api.openalex.org/works?filter=awards.id:G1745570270","primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9937,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9937,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0031,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0014,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":1.0},{"id":"https://openalex.org/keywords/molecular-alterations","display_name":"molecular alterations","score":0.676},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.702},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.91},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.684},{"id":"https://openalex.org/keywords/structural-reorganization","display_name":"structural rearrangement","score":0.812},{"id":"https://openalex.org/keywords/copy-number-variation","display_name":"copy number variation","score":0.853},{"id":"https://openalex.org/keywords/genome-editing","display_name":"genome editing","score":0.378},{"id":"https://openalex.org/keywords/phosphoproteomics","display_name":"phosphoproteomics","score":0.944},{"id":"https://openalex.org/keywords/transcriptomics","display_name":"transcriptomics","score":0.981},{"id":"https://openalex.org/keywords/metabolomics","display_name":"metabolomics","score":0.987},{"id":"https://openalex.org/keywords/clonal-evolution","display_name":"clonal evolution","score":0.836},{"id":"https://openalex.org/keywords/therapeutic-implications","display_name":"therapeutic implications","score":0.558}],"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537}],"institution_awarded":[{"id":"https://openalex.org/I4210086614","display_name":"Research Institute Hospital 12 de Octubre","ror":"https://ror.org/002x1sg85","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210086614"]}],"updated_date":"2026-11-13T03:01:57.000Z","created_date":"2026-07-13T04:51:35.000Z"}
